H.C. Wainwright Starts Scribe Therapeutics Inc (SCTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts SCTX Hot Sheet
Price: $21.17 +10.09%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
H.C. Wainwright initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Buy rating and a price target of $60.00.
For an analyst ratings summary and ratings history on Scribe Therapeutics Inc click here. For more ratings news on Scribe Therapeutics Inc click here.
Shares of Scribe Therapeutics Inc closed at $28.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: just concluded a highly successful discussion with president Vladimir Putin
- RBC on Semiconductor short interest as of September 30th
- Purebread Brands to acquire Caffè Artigiano in a $7.7M share deal
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
